GlassScriptPhysician profile
David Echeverri
NPI 1538665203
$3,415.23
in general payments reported to CMS, 2019-2025
32 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $1,056 · 2023: $1,021 · 2024: $569 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.42 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $489.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $421.78 | 2022-2025 | |
| Glaxosmithkline, LLC. | $282.00 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $224.22 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Theratechnologies INC. | $138.99 | 2022-2024 | Egrifta, Trogarzo |
| Amgen INC. | $91.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.97 | 2021-2024 | Takhzyro, Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.98 | 2021-2025 | Jardiance |
| Viiv Healthcare Company | $66.84 | 2022-2023 | Rukobia |
| Exact Sciences Corporation | $66.00 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $48.28 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.96 | 2022-2023 | Trulance, Xifaxan |
| Eisai INC. | $44.87 | 2021-2022 | |
| Philips North America LLC | $40.76 | 2025 | Mcot |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36.02 | 2022-2023 | Auvelity |
| Neos Therapeutics, LP | $31.30 | 2022-2023 | Adzenys Xr-Odt |
| Upsher-Smith Laboratories LLC | $27.13 | 2021 | |
| Kaleo, INC. | $23.95 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.66 | 2025 | Caplyta |
| Dexcom, INC. | $23.30 | 2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $21.89 | 2023 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $21.08 | 2021 | |
| Lundbeck LLC | $20.16 | 2023 | Vyepti |
| Almatica Pharma LLC | $19.86 | 2023 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $19.55 | 2024 | Voquezna |
| Gilead Sciences, INC. | $19.43 | 2023 | |
| Jazz Pharmaceuticals INC. | $17.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.09 | 2022 | |
| Tris Pharma INC | $14.42 | 2025 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2024 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Echeverri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.